서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 481 to 527 of 527

Issue DateTitle / Author(s) / CitationFileAltmetrics
2021
DNA Damage Repair Inhibitor for Breast Cancer Treatment

Min, Ahrum; Lee, Kyung-Hun; Im, Seock-Ah

Advances in Experimental Medicine and Biology, Vol.1187, pp.159-179

DOI
2021-01
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection
DOI
2021-01
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
DOI
2021-01
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE
DOI
2021-01
Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy
DOI
2021-01
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
DOI
2021-01
Association of insulin, metformin, and statin with mortality in breast cancer patients
DOI
2021-01
Development of a Novel Orthotopic Gastric Cancer Mouse Model
view fileDOI
2021-01
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
view fileDOI
2021-02
Genomic profile of metastatic breast cancer patient-derived xenografts established using biopsy sample
view filelink
2021-02
Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
DOI
2021-02
Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
DOI
2021-02
Intensity of metastasis screening and survival outcomes in patients with breast cancer
DOI
2021-04
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
DOI
2021-04
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
DOI
2021-04
New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12)
DOI
2021-05
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1(+) Activated T Cells
DOI
2021-06
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials
DOI
2021-07
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

Gelmon, Karen A.; Fasching, Peter A.; Couch, Fergus J.; Balmaña, Judith; Delaloge, Suzette; Labidi-Galy, Intidhar; Bennett, James; McCutcheon, Susan; Walker, Graham; O'Shaughnessy, Joyce; Collaborating Investigator; Timcheva, Constanta; Tomova, Antoaneta; Eisen, Andrea; Lemieux, Julie; Bazan, Fernando; Bourgeois, Hugues; Chakiba, Camille; Chehimi, Mohamad; Dalenc, Florence; De La Motte Rouge, Thibault; Frenel, Jean-Sébastien; Gonçalves, Anthony; Hardy-Bessard, Anne Claire; Lamy, Regine; Levy, Christelle; Lortholary, Alain; Mailliez, Audrey; Medioni, Jacques; Patsouris, Anne; Spaeth, Dominique; Teixeira, Luis; Tennevet, Isabelle; Villanueva, Cristian; You, Benoit; Ettl, Johannes; Gerber, Bernd; Hoffmann, Oliver; Park-Simon, Tjoung-Won; Reinisch, Mattea; Tio, Joke; Wimberger, Pauline; Boer, Katalin; Ballestrero, Alberto; Bianchini, Giampaolo; Biganzoli, Laura; Bordonaro, Roberto; Cognetti, Francesco; De Laurentiis, Michelino; De Placido, Sabino; Guarneri, Valentina; Montemurro, Filippo; Naso, Giuseppe; Santoro, Armando; Zamagni, Claudio; Kim, Seung-Jin; Nakamura, Seigo; Chae, Yee Soo; Cho, Eun Kyung; Hyun, Kim Jee; Im, Seock-Ah; Lee, Keun Seok; Park, Yeon Hee; Sohn, Joo Hyuk; Byrski, Tomasz; Huzarski, Tomasz; Kukielka-Budny, Bozena; Nowecki, Zbigniew; Szoszkiewicz, Renata; Tarnawski, Rafal; Dvornichenko, Viktoria; Moiseenko, Fedor; Mukhametshina, Guzel; Poddubskaya, Elena; Popova, Ekaterina; Tarasova, Anna; Vats, Anna; Adamo, Bárbara; Conejero, Raquel Andrés; Torres, Antonio Antón; Gelpi, Judith Balmaña; Fernández, Nieves Díaz; González, Alejandro Falcón; Garcia, Juan; Lorenzo-Lorenzo, Isabel; Antón, Fernando Moreno; Santisteban, Marta; Stradella, Agostina; Huang, Chiun-Sheng; Aksoy, Sercan; Arslan, Cagatay; Artac, Mehmet; Aydiner, Adnan; Ozyilkan, Ozgur; Sezer, Emel; Armstrong, Anne; Barrett, Sophie; Borley, Annabel; Kemp, Zoe; Michie, Caroline; Mukesh, Mukesh; Perren, Timothy; Swampillai, Angela; Young, Tammy

European Journal of Cancer, Vol.152, pp.68-77

DOI
2021-07
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
DOI
2021-07
Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report
DOI
2021-07
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES
DOI
2021-08
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
DOI
2021-08
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2,-3 and-7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
DOI
2021-08
Genomic Profiling of Premenopausal HR+ and HER2-Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
DOI
2021-08
Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts
DOI
2021-09
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
DOI
2021-10
Lymph Node Ratio after Neoadjuvant Chemotherapy for Stage II/III Breast Cancer: Prognostic Value Measured with Gini's Mean Difference of Restricted Mean Survival Times

Keam, Bhumsuk; Gorobets, Olena; Vinh-Hung, Vincent; Im, Seock-Ah

Cancer Informatics, Vol.20, pp.1-9

DOI
2021-10
Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)
DOI
2021-10
Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial

Lee, Kyung-Hun; Sohn, Joohyuk; Goodwin, Annabel; Usari, Tiziana; Lanzalone, Silvana; Im, Seock-Ah; Kim, Sung-Bae

Cancer Research and Treatment, Vol.53 No.4, pp.1084-1095

DOI
2021-12
Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis (KROG 16-12)
DOI
2021-12
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
DOI
2022
Do posttraumatic stress symptoms predict trajectories of sleep disturbance and fatigue in patients with breast cancer? A parallel-process latent growth model
DOI
2022-01
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
DOI
2022-02
Trastuzumab Emtansine plus Pertuzumab Versus Taxane plus Trastuzumab plus Pertuzumab after Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
DOI
2022-02
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
DOI
2022-02
Morning Chronotype Decreases the Risk of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer
DOI
2022-02
The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology
DOI
2022-03
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
DOI
2022-03
Psychiatric symptoms mediate the effect of resilience on health-related quality of life in patients with breast cancer: Longitudinal examination
DOI
2022-03
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study
DOI
2022-03
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
DOI
2022-03
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2(-) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
DOI
2022-04
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
DOI
2022-06
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial
DOI
2022-06
The longitudinal effects of chronotype on chemotherapy-induced nausea and vomiting in patients with breast cancer receiving neoadjuvant chemotherapy
DOI
2023
Mechanism of Lapatinib Resistance in SK-BR-3 Breast Cancer Cells
view filelink
15 6 7 8 9